Orbis Medicines to Expand With New R&D Site in Copenhagen
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a significant expansion of its operations and capabilities by establishing itself at Symbion’s new biotech hub in Fuglebakken, Copenhagen.
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases.
Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.